30 Humans, 8 Votes, and the Future of FDA Drug Approval

01What Are Peptides?

Peptides are short chains of amino acids — the building blocks of proteins. The human body uses 20 fundamental amino acids, and when they combine in short chains, they form peptides. These molecules help regulate different functions in the body, from hormone signaling to tissue repair to immune response.

Some peptides are well-established, FDA-approved drugs. Insulin is a peptide. Semaglutide (the active ingredient in Ozempic) is a peptide. These have passed full clinical trials with thousands of patients, demonstrated safety and efficacy, and gone through the standard FDA approval process.

But many more peptides — at least 17 currently listed by the FDA — are not approved. They have not been proven safe or effective. They include compounds like BPC-157, KPV, and others promoted by influencers and wellness clinics for muscle recovery, wound healing, anti-inflammation, and anti-aging. Until three years ago, people could get these through compounding pharmacies, which made them from raw ingredients. The FDA banned that practice in 2023, citing "significant safety concerns" including the risk of life-threatening allergic reactions.

02The 8-6 Vote That Changed Everything

The advisory panel split 8 to 6 in favor of allowing compounding pharmacies to make the first peptide under review. That vote was not random. It mapped exactly to the panel's composition.

The six no votes came from the academics and researchers — the kind of scientists who have traditionally served on FDA advisory committees. They looked at the data (or lack of it) and voted no.

The eight yes votes included four new members added to the panel the previous month by Health Secretary RFK Jr. These are people who promote, prescribe, or produce peptides. They voted to allow compounding. The math is simple: without those four appointees, the vote would have been 4-6 against.

03The Data Gap

Here is what makes this vote remarkable. The first peptide to pass had clinical studies with a total of 30 humans. Not 30,000. Not 3,000. Thirty.

For context, a standard FDA drug approval typically requires three phases of clinical trials. Phase 1 tests safety in 20-80 healthy volunteers. Phase 2 tests efficacy and side effects in 100-300 patients. Phase 3 tests in 1,000-3,000 patients across multiple sites. A drug that completes Phase 3 has been studied in thousands of people under controlled, randomized, placebo-controlled conditions.

These peptides have not completed Phase 1 by that standard. And they are being voted through for compounding pharmacy access.

04The Seven Peptides Under Review

The advisory panel reviewed seven specific peptides this week. Here is what is known about each:

What does "minimal human" mean? Open-label trials — meaning not placebo-controlled. Someone gives a peptide, they know they are getting a peptide, the physician knows they are giving a peptide, and they follow really small numbers of patients to see what happens. That is not the kind of data the FDA typically requires for approval.

05The Gray Market

The FDA banned compounding pharmacies from making these peptides three years ago, citing significant safety concerns including the risk of life-threatening allergic reactions. That ban hardly made a dent in demand. The peptides were still widely bought and used, mostly through unregulated markets.

Vendors skirted the rules by labeling the peptides "for research use only." This is the gray market — unregulated, uninspected, and unaccountable. The products come from raw ingredient suppliers, many in India and China, with no FDA oversight of the manufacturing process.

This is RFK Jr.'s core argument, and it is not unreasonable on its face: people are injecting these substances anyway. They are buying them from unregulated gray-market vendors with zero oversight. Bringing compounding pharmacies back into the regulated supply chain makes the products safer, even if the clinical data is thin. You are not approving the peptide — you are approving the supply chain.

The problem is that this logic applies to any unapproved drug. People take all kinds of untested substances. The FDA's answer has always been: do not make it easier to get them. Make it harder. Ban the gray market. Do not legitimate the compound.

06The Market Behind the Movement

The global peptide market is projected to more than double by 2034. This is not a niche wellness trend anymore. It is a rapidly growing industry with influencer marketing, celebrity endorsements, and political backing from the Health Secretary of the United States.

07The Timeline

08The Real Question

This story is about peptides, but it is also about something bigger: how the FDA approves drugs going forward.

The traditional standard is simple: prove a drug is safe and effective through rigorous clinical trials before allowing widespread access. That standard has been in place for decades. It is the reason the United States has not had another thalidomide disaster.

RFK Jr.'s approach reverses that logic: look for a safety signal after the drug is in use. If there is one, remove it. If there is not, leave it. "Look for a safety signal and if there is one, then you move it. But if there's not one, then you don't."

09What Happens Next

The advisory committee's vote is not binding. The FDA will take the recommendations under advisement and make a final decision. Six more peptides are still under review. Each will get its own vote.

If the FDA accepts the recommendation, it will reverse a ban it imposed three years ago and open the door to compounding peptides with minimal clinical data. If it rejects the recommendation, it will overrule its own advisory panel — a politically charged move given that the panel was stacked by the Health Secretary to produce this exact result.

Either way, the precedent is set. A Health Secretary can stack an advisory panel, shift the vote, and push through access to untested drugs. The next secretary can do the same. The question is not whether this particular peptide is safe. The question is whether the process that approved it is safe. And that process just changed.